Akebia Therapeutics Inc represents values of innovation, collaboration, and patient-centricity. The company strives to develop novel therapies to address unmet medical needs and improve patient outcomes. Akebia embraces a corporate philosophy centered around scientific excellence, integrity, and a commitment to advancing healthcare. By conducting rigorous research and fostering partnerships, Akebia aims to revolutionize the treatment landscape for patients worldwide. With a focus on bringing transformative therapies to market, Akebia Therapeutics Inc is dedicated to enhancing the lives of patients and making a lasting impact on the healthcare industry.

Akebia Therapeutics Inc primarily operates in the United States and has a significant presence in various regions within the country. As a biopharmaceutical company, Akebia Therapeutics focuses on discovering, developing, and commercializing innovative therapies to address unmet medical needs. With its headquarters located in Cambridge, Massachusetts, Akebia Therapeutics caters to patients across the United States, offering its specialized treatments for conditions such as anemia caused by chronic kidney disease. This American-based company's commitment to improving patient outcomes and advancing medical research has solidified its position in the healthcare industry.

Akebia Therapeutics Inc has achieved several significant milestones. The company successfully received marketing approval for its drug, Auryxia, which is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease. Akebia has also entered into collaborations with top pharmaceutical companies to further develop and commercialize its products. Additionally, the company has conducted successful clinical trials for its investigational drug, Vadadustat, as a potential treatment for anemia associated with chronic kidney disease. Akebia Therapeutics Inc has shown consistent growth and innovation in the pharmaceutical industry, positioning itself as a leading player in the development of therapies for renal and metabolic disorders.

Akebia Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with kidney disease. Founded in 2007, the company has a strong history in researching and developing novel drugs targeted at treating anemia and other complications of chronic kidney disease. Akebia Therapeutics Inc has built a robust pipeline of potential therapies, with its lead product candidate being vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. The company strives to improve patient outcomes and enhance their quality of life through its dedication to advancing kidney disease treatments. Akebia Therapeutics Inc has become a recognized name in the pharmaceutical industry due to its commitment to innovation and research in the field of kidney disease.

The main competitors of Akebia Therapeutics Inc in the market include pharmaceutical companies such as FibroGen Inc, GlaxoSmithKline plc, and Keryx Biopharmaceuticals Inc.

Akebia Therapeutics Inc is primarily active in the biopharmaceutical industry. Their focus lies in the research, development, and commercialization of innovative therapies to address unmet medical needs. With a dedication to addressing kidney diseases and other serious conditions, Akebia Therapeutics Inc aims to improve patient outcomes and quality of life. Through their strategic partnerships and robust pipeline, the company aims to advance their therapeutic solutions and make a positive impact in the healthcare sector.

The business model of Akebia Therapeutics Inc is focused on the development and commercialization of innovative therapeutics for patients with kidney diseases. Akebia employs a research-driven approach to develop therapies that address unmet medical needs in the kidney disease market. The company's flagship product, Auryxia, is an oral medication approved for the treatment of anemia due to chronic kidney disease in adult patients. Akebia is also engaged in developing potential treatments for other kidney-related conditions, such as diabetic kidney disease. By leveraging its scientific expertise and strategic partnerships, Akebia aims to improve patient outcomes and contribute to the advancement of kidney disease management.

P/E odnos Akebia Therapeutics iznosi -5,99.

KUV kompanije Akebia Therapeutics iznosi 1,78.

AlleAktien kvalitativni skor za Akebia Therapeutics je 4/10.

očekivana Akebia Therapeutics promet je 175,44 mil. USD.

Dobit očekivana Akebia Therapeutics je -52,19 mil. USD.

Akebia Therapeutics Inc is a biopharmaceutical company focusing on the development and commercialization of innovative therapies for the treatment of kidney diseases. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. Akebia's business model is based on the development and commercialization of products for the treatment of anemia, a common complication in chronic kidney diseases. The company specializes in developing therapies that can increase hemoglobin levels in the blood and slow the progression of kidney disease. Akebia has already developed several products that are in different stages of clinical development. One of Akebia's leading products is Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vadadustat is currently in Phase III trials to evaluate its effectiveness and safety in patients with advanced-stage chronic kidney disease. Akebia has also entered into an agreement with Otsuka Pharmaceutical Co. Ltd., a leading Japanese pharmaceutical company. The agreement stipulates that Otsuka will market Vadadustat in Japan and most other Asian countries. Akebia will be responsible for the development, manufacturing, and marketing of Vadadustat in the US and Europe. Furthermore, Akebia has other promising products in the pipeline, including AKB-5169, another oral medication for the treatment of anemia in patients with chronic kidney disease. AKB-5169 is currently in Phase II trials. The company has also established a strong partnership with Mitsubishi Tanabe Pharma Corporation. This partnership focuses on the development and commercialization of therapies for the treatment of kidney diseases. Akebia will handle the development and manufacturing of therapies, while Mitsubishi Tanabe Pharma Corporation will be responsible for the marketing and distribution in Japan. Akebia has also focused on building a strong research and development department. The company has developed a platform technology called HIF (Hypoxia Inducible Factor), which enables the discovery and development of new therapies for the treatment of kidney diseases. This technology utilizes the body's natural mechanism to increase oxygen transport in the blood. Overall, Akebia has built a promising business model based on the development and commercialization of innovative therapies for the treatment of kidney diseases. The company has already developed several promising products in the pipeline and established strong partnerships with leading pharmaceutical companies. Akebia also has a strong research and development department, allowing the company to continue discovering and developing new therapies for the treatment of kidney diseases.

Akebia Therapeutics isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Akebia Therapeutics trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Akebia Therapeutics je US00972D1054.

WKN od Akebia Therapeutics je A1XF0S.

Oznaka za praćenje akcija kompanije Akebia Therapeutics je AKBA.

U poslednjih 12 meseci, Akebia Therapeutics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Akebia Therapeutics će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Akebia Therapeutics trenutno iznosi .

Akebia Therapeutics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Akebia Therapeutics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Akebia Therapeutics se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Akebia Therapeutics od 30. 10. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 30. 10. 2024..

Isplata poslednje dividende izvršena je 30. 10. 2024..

U godini 2023 kompanija Akebia Therapeutics je isplatila 0 USD kao dividende.

Dividende od Akebia Therapeutics se isplaćuju u USD.